Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
Investor's Business Daily on MSN
Merck stock zooms closer to a breakout on 'a new chapter' in cancer
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results